Mechanisms underlying joint pain

Drug Discovery Today: Disease Mechanisms

Volumn 3, Issue 3, 2006, Pages 357-363

  Nagy, Istvan ^a   Lukacs, Katalin V ^b   Urban, Laszlo ^c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^c Discovery Technologies   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [5 CHLORO 2 [2 [4 (4 FLUOROBENZYL) 2 METHYL 1 PIPERAZINYL] 2 OXOETHOXY]PHENYL]UREA; ACID SENSING ION CHANNEL; ADALIMUMAB; BRADYKININ; BRADYKININ ANTAGONIST; CANNABINOID RECEPTOR; CAPSAICIN; CELECOXIB; CHEMOKINE RECEPTOR ANTAGONIST; CP 481715; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DRONABINOL; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; ION CHANNEL; ION TRANSPORT AFFECTING AGENT; LUMIRACOXIB; METHOTREXATE; MORPHINE; NEUROPEPTIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; PSALMOTOXIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RESINIFERATOXIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ARTHRALGIA; BONE REMODELING; CENTRAL NERVOUS SYSTEM; CHRONIC PAIN; CLINICAL TRIAL; DESENSITIZATION; DISEASE ACTIVITY; DRUG MECHANISM; HUMAN; HYPERALGESIA; NERVE FIBER C; NEUROGENIC INFLAMMATION; NEUROTRANSMITTER RELEASE; NOCICEPTION; NOCICEPTIVE RECEPTOR; NONHUMAN; OSTEOARTHRITIS; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS;

EID: 33847026969     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2006.10.002     Document Type: Review

References (58)

1. Schaible H.G., et al. Mechanisms of pain in arthritis. Ann. N.Y. Acad. Sci. 966 (2002) 343-354
2. Kidd B.L. Osteoarthritis and joint pain. Pain 123 (2006) 6-9 [Epub]
3. Schaible H.G., and Grubb B.D. Afferent and spinal mechanisms of joint pain. Pain 55 (1993) 5-54
4. Kress M., and Reeh P.W. Chemical excitation and sensitization in nociceptors. In: Belmomte C., and Cervero F. (Eds). Neurobiology of Nociceptors (1996), Oxford University Press 258-297
5. Heppelmann B. Anatomy and histology of joint innervation. J. Peripher. Nerv. Syst. 2 (1997) 5-16
6. Macefield V.G. Physiological characteristics of low-threshold mechanoreceptors in joints, muscle and skin in human subjects. Clin. Exp. Pharmacol. Physiol. 32 (2005) 135-144
7. Schaible H.G., and Schmidt R.F. Responses of fine medial articular nerve afferents to passive movements of knee joints. J. Neurophysiol. 49 (1983) 1118-1126
8. Schaible H.G., and Schmidt R.F. Activation of groups III and IV sensory units in medial articular nerve by local mechanical stimulation of knee joint. J. Neurophysiol. 49 (1983) 35-44
9. Ivanavicius S.P., et al. Isolectin B4 binding neurons are not present in the rat knee joint. Neuroscience 128 (2004) 555-560
10. Kuniyoshi K., et al. Characteristics of sensory DRG neurons innervating the wrist joint in rats. Eur. J. Pain (2006) [Epub.]
11. Carlton S.M., and Coggeshall R.E. Inflammation-induced upregulation of neurokinin-1 receptors in rat glabrous skin. Neurosci. Lett. 326 (2002) 29-32
12. Lewin G.R., et al. Peripheral and central mechanisms of NGF-induced hyperalgesia. Eur. J. Neurosci. 6 (1994) 1903-1912
13. Klede M., et al. Central origin of mechanical hyperalgesia. J. Neurophysiol. 90 (2003) 353-359
14. Weidner C., et al. Functional attributes discriminating mechano-insensitive and mechano-responsive C nociceptors in human skin. J. Neurosci. 19 (1999) 10184-10190
15. Orstavik K., et al. Pathological C fibers in patients with a chronic painful condition. Brain (2003) 567-578
16. Schaible H.G., et al. Pathophysiology and treatment of pain in joint disease. Adv. Drug Deliv. Revs. 58 (2006) 323-342
17. Stein C., et al. Peripheral analgesic and anti-inflammatory effects of opioids. Z. Rheumatol. 60 (2001) 416-424
18. Just S., and Heppelmann B. Neuropeptide Y changes the excitability of fine afferent units in the rat knee joint. Br. J. Pharmacol. 132 (2001) 703-708
19. Powell K.J., et al. Inhibition of neurokinin-1-substance P receptor and prostanoid activity prevents and reverses the development of morphine tolerance in vivo and the morphine-induced increase in CGRP expression in cultured dorsal root ganglion neurons. Eur. J. Neurosci. 18 (2003) 1572-1583
20. Bar K.J., et al. The expression and localization of somatostatin receptors in dorsal root ganglion neurons of normal and monoarthritic rats. Neuroscience 127 (2004) 197-206
21. Voilley N. Acid-sensing ion channels (ASICs): new targets for the analgesic effects of non-steroid anti-inflammatory drugs (NSAIDs). Curr. Drug Targets Inflamm. Allergy 3 (2004) 71-79
22. Kobayashi K., et al. Distinct expression of TRPM8, TRPA1, and TRPV1 mRNAs in rat primary afferent neurons with adelta/c-fibers and colocalization with trk receptors. J. Comp. Neurol. 493 (2005) 596-606
23. Nagy I., et al. The role of the vanilloid receptor (TRPV1) in physiology and pathology. Eur. J. Pharmacol. 500 (2004) 351-369
24. Numazaki M., and Tominaga M. Nociception and TRP channels. Curr. Drug Targets CNS Neurol. Disord. 3 (2004) 479-485
25. Charo I.F., and Ransohoff R.M. The many roles of chemokines and chemokine receptors in inflammation. New Engl. J. Med. 354 (2006) 610-621
26. Jolliffe V.A., et al. Assessment of cutaneous sensory and autonomic axon reflexes in rheumatoid arthritis. Ann. Rheum. Dis. 54 (1995) 251-255
27. Deal C.L. Treatment of arthritis with topical capsaicin: a double-blind trial. Clin. Ther. 13 (1991) 383-395
28. McCleane G. The analgesic efficacy of topical capsaicin is enhanced by glyceryl trinitrate in painful osteoarthritis: a randomized, double blind, placebo controlled study. Eur. J. Pain. 4 (2000) 355-360
29. Ringkamp M., et al. Capsaicin responses in heat-sensitive and heat-insensitive A-fiber nociceptors. J. Neurosci. 21 (2001) 4460-4468
30. Schmidt R., et al. Novel classes of responsive and unresponsive C nociceptors in human skin. J. Neurosci. 15 (1995) 333-341
31. Neugebauer V., et al. Calcitonin gene-related peptide is involved in the spinal processing of mechanosensory input from the rat's knee joint and in the generation and maintenance of hyperexcitability of dorsal horn neurons during development of acute inflammation. Neuroscience 71 (1996) 1095-1109
32. Neugebauer V., et al. Inveolvement of substance P and neurokinin-1 reeceptors in the hyperexcitability of dorsal horn neurons during development of acute arthritis in rat's knee joint. J. Neurophysiol. 73 (1995) 1574-1583
33. Urban L., et al. Modulation of spinal excitability: Cooperation between neurokinin and excitatory amino acid transmitters. Trends Neurosci. 17 (1994) 432-438
34. Geba G.P., et al. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. J. Am. Med. Assoc. 287 (2002) 64-71
35. Dionne R.A., et al. Analgesia and COX-2 inhibition. Clin. Exp. Rheumatol. 19 (2001) 63-70
36. Zhang Y., et al. Inhibition of cyclooxygenase-2 rapidly reverses inflammatory hyperalgesia and prostaglandin E2 production. J. Phamacol. Exp. Ther. 283 (1997) 1069-1075
37. England S., et al. PGE2 modulates the tetrodotoxin-resistant sodium current in neonatal rat dorsal root ganglion neurons via the cyclic AMP-protein kinase A cascade. J. Physiol. (Lond) 495 (1996) 429-440
38. Taylor P.C., et al. VEGF release is associated with hypoxia in inflammatory arthritis. Arthritis Rheum. 43 Suppl. 9 (2000) S296
39. Nagae M., et al. Osteoclasts play a part in pain due to the inflammation adjacent to bone. Bone (2006 Jun 10) [Epub ahead of print]
40. Ribeiro S., and Horuk R. The clinical potential of chemokine receptor antagonists. Pharmacol. and Therap. 107 (2005) 44-58
41. Nanes M.S. Tumor necrosis factor-α: Molecular and cellular mechanisms in skeletal pathology. Gene 321 (2003) 1-15
42. Hochberg M.C., et al. Comparison of the efficacy of the tumor necrosis alpha blocking agents adalimumab, etanercept and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann. Rheum. Dis. suppl. 2 (2003) ii13-ii16
43. Hoheisel U., et al. Excitatry and modulatory effects of inflammatory cytokines and neurotrophins on mechanosensitive group IV muscle afferents in the rat. Pain 114 (2005) 168-176
44. Samad T.A., et al. Interleukin-1β-mediated induction of COX-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 410 (2001) 471-475
45. Schaefers M., et al. Tumor necrosis factor-α induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. J. Neurosci. 23 (2003) 2517-2521
46. Tonussi C.R., and Ferreira S.H. Bradykinin-induced knee joint incapacitation involves bradykinin B2 receptor mediated hyperalgesia and bradykinin B1 receptor mediated nociception. Eur. J. Pharmacol. 326 (1997) 61-65
47. Cruwys S.C., et al. The role of bradykinin B1 receptors in the maintenance of intra articular plasma extravasation in chronic antigen-induced arthritis. Br. J. Pharmacol. 113 (1994) 940-944
48. Danese S., et al. Biological therapies for inflammatory bowel disease: research drives clinics. Mini Revs. In Med. Chem. 6 (2006) 771-784
49. Nuki G., et al. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: Extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46 (2002) 2838-2846
50. Hinz B., and Brune K. Pain and osteoarthritis: new drugs and mechanisms. Curr. Opin. Rheumatol. 16 (2004) 628-633
51. Gibofsky A., et al. Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial. Arthritis Rheum. 48 (2003) 3102-3111
52. Goodwin J.L., et al. The use of opioids in the treatment of osteoarthritis: when, why, and how?. Curr. Pain Headache Rep. 9 (2005) 390-398
53. Romanovsky A.A., et al. Microsomal prostaglandin E synthase-1, ephrins, and ephrin kinases as suspected therapeutic targets in arthritis: exposed by "criminal profiling". Ann. N. Y. Acad. Sci. 1069 (2006) 183-194
54. Avelino A., and Cruz F. TRPV1 (vanilloid receptor) in the urinary tract: expression, function and clinical applications. Naunyn Schmiedebergs Arch. Pharmacol. 373 (2006) 287-299 [Epub 2006 May 24]
55. Gladue R.P., et al. CP-481,715, a potent and selective CCR1 antagonist with potential therapeutic implications for inflammatory diseases. J. Biol. Chem. 278 (2003) 40473-40480
56. Akopian A.N., et al. The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways. Nat. Neurosci. 2 (1999) 541-548
57. Fortin J.P., and Marceau F.O. Advances in the development of bradykinin receptor ligands. Curr. Top. Med. Chem. 6 (2006) 1353-1363
58. Svendsen K.B., et al. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. Br. Med. J. 329 (2004) 253